<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Otsuka Holdings Co., Ltd. Otsuka Group News RSS</title>
    <link>http://www.otsuka.com</link>
    <description>Otsuka Holdings Co., Ltd. Otsuka Group News RSS</description>
    <atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="http://www.otsuka.com/en/group_news/rss.php" type="application/rss+xml" rel="self"/>
    <pubDate>Fri, 25 Sep 2026 09:00:00 +0900</pubDate>
    <lastBuildDate>Fri, 25 Sep 2026 09:00:00 +0900</lastBuildDate>
    <ttl>60</ttl>
    <item>
      <title>Otsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of January 1, 2027</title>
      <link>https://www.otsukafoods.co.jp/en/news/20260925.html</link>
      <description/>
      <pubDate>Fri, 25 Sep 2026 09:00:00 +0900</pubDate>
      <news_id>1628</news_id>
    </item>
    <item>
      <title>Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260924_1.html</link>
      <description/>
      <pubDate>Thu, 24 Sep 2026 09:00:00 +0900</pubDate>
      <news_id>1626</news_id>
    </item>
    <item>
      <title>Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260922_1.html</link>
      <description/>
      <pubDate>Tue, 22 Sep 2026 09:00:00 +0900</pubDate>
      <news_id>1627</news_id>
    </item>
    <item>
      <title>Otsuka and Jolly Good Launch New Content for FACEDUO Dementia Care Support VR Understanding a New Perspective on Dementia</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260918_1.html</link>
      <description/>
      <pubDate>Fri, 18 Sep 2026 09:00:00 +0900</pubDate>
      <news_id>1625</news_id>
    </item>
    <item>
      <title>EN Otsuka Pharmaceutical Obtains Marketing Approval for ENOFEED® Liquid for Enteral Use</title>
      <link>https://www.otsukakj.jp/en/news_release/20260916.html</link>
      <description/>
      <pubDate>Wed, 16 Sep 2026 09:00:00 +0900</pubDate>
      <news_id>1624</news_id>
    </item>
    <item>
      <title>Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer</title>
      <link>https://www.taiho.co.jp/en/release/2026/20260914.html</link>
      <description/>
      <pubDate>Mon, 14 Sep 2026 09:00:00 +0900</pubDate>
      <news_id>1623</news_id>
    </item>
    <item>
      <title>Otsuka Holdings Publishes “Integrated Report 2026”</title>
      <link>http://www.otsuka.com/en/group_news/detail.php?id=1622</link>
      <description>Otsuka Holdings Publishes “Integrated Report 2026”</description>
      <pubDate>Thu, 03 Sep 2026 09:00:00 +0900</pubDate>
      <news_id>1622</news_id>
    </item>
    <item>
      <title>Otsuka Holdings Enters into Virtual PPA with Special Purpose Company Established with Sojitz   –Advancing Carbon Neutral Initiatives through Expansion of Self-Generated Renewable Energy–</title>
      <link>http://www.otsuka.com/en/group_news/detail.php?id=1621</link>
      <description>Otsuka Holdings Enters into Virtual PPA with Special Purpose Company Established with Sojitz  –Advancing Carbon Neutral Initiatives through Expansion of Self-Generated Renewable Energy–</description>
      <pubDate>Fri, 28 Aug 2026 09:00:00 +0900</pubDate>
      <news_id>1621</news_id>
    </item>
    <item>
      <title>SOYJOY Matcha &amp; Yuzu Rich and Intense Matcha Flavor with the Vibrant Aroma of Yuzu</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260820_1.html</link>
      <description/>
      <pubDate>Thu, 20 Aug 2026 09:00:00 +0900</pubDate>
      <news_id>1618</news_id>
    </item>
    <item>
      <title>Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer（Link to Taiho Oncology website）</title>
      <link>https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-first-line-phase-3-rezilient3-trial-data-selected-for-presidential-symposium-presentation-at-the-iaslc-2026-world-conference-on-lung-cancer/</link>
      <description/>
      <pubDate>Thu, 20 Aug 2026 09:00:00 +0900</pubDate>
      <news_id>1619</news_id>
    </item>
  </channel>
</rss>
